Adjuvant Therapies of Cancer (häftad)
Fler böcker inom
Format
Häftad (Paperback / softback)
Språk
Engelska
Antal sidor
358
Utgivningsdatum
2012-02-22
Upplaga
Softcover reprint of the original 1st ed. 1982
Förlag
Springer-Verlag Berlin and Heidelberg GmbH & Co. K
Medarbetare
Bonadonna, G. (ed.), Mathe (ed.), Salmon, S. (ed.), AAe (ed.), Georges (ed.)
Illustrationer
XVI, 358 p.
Dimensioner
244 x 170 x 20 mm
Vikt
604 g
Antal komponenter
1
Komponenter
1 Paperback / softback
ISBN
9783642816871

Adjuvant Therapies of Cancer

Häftad,  Engelska, 2012-02-22
1174
  • Skickas från oss inom 10-15 vardagar.
  • Fri frakt över 249 kr för privatkunder i Sverige.
Transplantation of syngeneic (donor is a monozygous twin) or allogeneic (donor is an HLA-identical sibling) marrow provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity. Until 1975, marrow transplantation was carried out only after failure of all other therapy. Consequently, most patients were in advanced relapse. Six of 16 recipients of syngeneic marrow and 13 of 100 recipients of allogeneic marrow are still in remission after 5. 5-10 years [3, 7]. An actuarial survival curve of the first 100 patients grafted in Seattle after conditioning with cyclophos phamide (60 mg/kg on each of 2 successive days) and total body irradiation (1,000 rad) showed three periods of interest: (1) The first 4 months showed a rapid loss of patients associated with advanced illness, graft-versus-host disease, infections (in particular interstitial pneumonias), and recurrent leukemia; (2) from 4 months to 2 years, the curve showed a much slower rate of decline attributable primarily to recurrent leukemia; and (3) from 2-10 years, the curve was almost flat with a negligible loss of patients and no recurrent leukemia. This flat portion of the curve corresponded to 13% of the patients and indicates a strong probability that the majority of these survivors are cured of their disease [8]. Attempts at reducing the incidence of leukemic relapse after transplantation were made by a number of marrow transplant groups by added chemotherapy.
Visa hela texten

Passar bra ihop

  1. Adjuvant Therapies of Cancer
  2. +
  3. Illustrated Dental Embryology, Histology, and Anatomy

De som köpt den här boken har ofta också köpt Illustrated Dental Embryology, Histology, and A... av Margaret J Fehrenbach (häftad).

Köp båda 2 för 2068 kr

Kundrecensioner

Har du läst boken? Sätt ditt betyg »

Fler böcker av författarna

Innehållsförteckning

I. General Considerations.- 1. Metastatic Potential of Metastases, Tumor Cell Heterogeneity, and Therapeutic Implications.- 2. Immune Imbalance and Immune Modulation in Solid Tumor Patients: New Insights.- 3. Markers of Minimal Residual Disease.- 4. Radiotherapy as Adjuvant Local Therapy of Local Tumors.- II. Hemopoietic and Lymphoid Neoplasias.- 5. Comparison of HLA Phenotypes in Long-Term Survivors with Acute Lymphoblastic Leukemia Treated with Immunotherapy Versus Chemotherapy.- 6. An Intensive Chemo- or Chemoimmunotherapy Regimen for Patients with Intermediate and Poor- Prognosis Acute Lymphatic Leukemia and Leukemic Lymphoblastic Lymphosarcoma: Preliminary Results with 14-Month Median Follow-Up.- 7. Poor-Prognosis Acute Lymphoblastic Leukemias.- 8. Therapeutic Effectiveness of Neuraminidase- Treated Allogeneic Myeloblasts as Immunogen in Acute Myelocytic Leukemia.- 9. Maintenance Chemoimmunotherapy of Nonlymphoblastic Acute Leukemias.- 10. Possible Mechanisms of Immunotherapy Action in Acute Nonlymphatic Leukemia: Macrophage Production of Colony-Stimulating Activity.- 11. The Finnish Leukaemia Group: Levamisole in Maintenance Therapy of Acute Myeloid Leukemia in Adults.- 12. Treatment of Acute Leukemia in Remission by Bone Marrow Transplantation.- 13. Prevention of Blastic Crisis in Ph1 -Positive Chronic Myeloid Leukemia.- 14. A Southwest Oncology Group: Chemotherapy Versus Chemotherapy Plus Radiotherapy in Treatment of Stage III Hodgkins Disease.- 15. Maintenance Immunotherapy with BCG in Non-Hodgkins Malignant Lymphomas: A Progress Report of a Randomized Trial.- III. Bone Tumors.- 16. Role of Lung Irradiation in the Adjuvant Treatment of Osteosarcoma.- 17. Adjuvant Interferon Treatment of Human Osteosarcoma.- 18. A Strategic Adjuvant Therapy ofOsteosarcoma.- 19. Ewings Sarcoma: Treatment with High-Dose Radiation and Adjuvant Chemotherapy.- 20. Adjuvant Chemotherapy in Ewings Sarcoma Patients.- 21. Early Results of Combined Modality Therapy of Patients with Ewings Sarcoma.- 22. Ewings Sarcoma: 5-Year Survival Under Adjuvant Chemotherapy.- IV. Breast Carcinoma.- 23. Natural History of Breast Cancer.- 24. Adjuvant Chemotherapy in Breast Cancer.- 25. Multimodal Therapy with CMF in Resectable Breast Cancer with Positive Axillary Nodes: The Milan Institute Experience.- 26. Follow-Up Results from a Randomized Trial for T3 and T4 Breast Cancer Patients: Previous BCG Immunotherapy Improves Response to Chemotherapy in the Relapse Patient.- 27. Adjuvant Treatment of Node-Positive Breast Cancer with Adriamycin-Cyclophosphamide with or Without Radiation Therapy: Interim Results of an Ongoing Clinical Trial.- 28. A Randomized Trial of Postoperative Five- Versus Three-Drug Chemotherapy After Mastectomy: A Cancer and Leukemia Group B (CALGB) Study.- 29. Adjuvant Chemoimmunotherapy with LMF Plus BCG in Node-Negative and Node-Positive Breast Cancer Intermediate Report at 4 Years.- 30. Adjuvant Intermittent Chemoimmunotherapy for Primary Breast Cancer: A Prospective Study with Immunologic Follow-Up.- 31. Short-Term and Long-Term Effects of Chemoimmunotherapy on Granulopoiesis: Adjuvant Therapy of Breast Cancer.- 32. A New Adjuvant Treatment with Polyadenylic- Polyuridylic Acid in Operable Breast Cancer.- V. Lung Carcinoma.- 33. Metastatic CNS Disease in Small Cell Carcinoma of the Bronchus: The Role of Radiotherapy and Chemotherapy.- 34. Interim Results of EORTC Protocol 08742: Comparison, After Irradiation of Locally Advanced Squamous Cell Bronchial Carcinoma, of Abstention, Immunotherapy, CombinationChemotherapy or Chemoimmunotherapy.- 35. Immunologically Defined Prognostic Subgroups as Predictors of Response to BCG Immunotherapy.- 36. Intrapleural BCG Immunotherapy of Lung Cancer Patients.- 37. Specific Active Immunotherapy in Lung Cancer: The Induction of Long-Lasting Cellular Responses to Tumour-Associated Antigens.- 38. Malnutrition in Lung Cancer: Incidence, Prognostic Implications, and Pathogenesis.- 39. Foll